Literature DB >> 33402521

The Impact of Peripheral Eosinophil Counts and Eosinophil to Lymphocyte Ratio (ELR) in the Clinical Course of COVID-19 Patients: A Retrospective Study.

Vasiliki E Georgakopoulou1,2, Nikolaos Garmpis3,4, Christos Damaskos5,6, Serena Valsami7, Dimitrios Dimitroulis3, Evangelos Diamantis8, Paraskevi Farmaki9, Chrysovalantis V Papageorgiou1, Sotiria Makrodimitri1, Nikolaos Gravvanis10, Stamatis Velonias10, Pagona Sklapani11, Nikolaos Trakas12, Efstathios A Antoniou3,4, Konstantinos Kontzoglou3,4, Lampros Nikolidakis13, Zoi Damaskou13, Athanasios Syllaios14, Georgios Marinos15, Georgia Vogiatzi15, Georgia-Eleni Korrou15, Georgios Kyriakos16, Lourdes-Victoria Quiles-Sanchez17, Alexandros Patsouras18, Dimitrios Lamprinos15, Athanasia Stelianidi9, Spyridon Savvanis19, Anna Garmpi20.   

Abstract

BACKGROUND/AIM: Eosinophils are blood cells responsible for response against parasites and allergens. Eosinophil to lymphocyte ratio (ELR) is a biomarker for inflammatory conditions. Our aim was to evaluate the role of eosinophils and ELR in COVID-19 patients. PATIENTS AND METHODS: The study included 96 patients hospitalized with COVID-19. They were classified into moderate to severe cases and critical cases. Eosinophils and ELR were determined in both groups, in patients that died or survived and were correlated to duration of hospitalization.
RESULTS: There was a statistically significant decrease in eosinophils and ELR between patients that died and patients that survived (p<0.05), and in mean values of the two biomarkers (p<0.05 for eosinophils and p<0.05 for ELR) between patients hospitalized for more or less than 15 days among those with moderate to severe disease.
CONCLUSION: Lower eosinophil counts and ERL could probably predict worse outcome in COVID-19 patients. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  COVID-19; Eosinophils; biomarker; lymphocyte; prediction; ratio

Mesh:

Substances:

Year:  2021        PMID: 33402521      PMCID: PMC7880766          DOI: 10.21873/invivo.12303

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  25 in total

1.  Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus.

Authors:  Amali E Samarasinghe; Rossana C N Melo; Susu Duan; Kim S LeMessurier; Swantje Liedmann; Sherri L Surman; James J Lee; Julia L Hurwitz; Paul G Thomas; Jonathan A McCullers
Journal:  J Immunol       Date:  2017-03-10       Impact factor: 5.422

Review 2.  Eosinophils and Respiratory Viruses.

Authors:  Armando S Flores-Torres; Mario C Salinas-Carmona; Eva Salinas; Adrian G Rosas-Taraco
Journal:  Viral Immunol       Date:  2019-05-29       Impact factor: 2.257

3.  Eosinopenia and COVID-19.

Authors:  Fahmina Tanni; Eleonora Akker; Muhammad M Zaman; Nilka Figueroa; Biju Tharian; Kenneth H Hupart
Journal:  J Am Osteopath Assoc       Date:  2020-07-16

4.  Risk factors for disease progression in COVID-19 patients.

Authors:  Min Cheol Chang; Yu-Kyung Park; Bong-Ok Kim; Donghwi Park
Journal:  BMC Infect Dis       Date:  2020-06-23       Impact factor: 3.090

5.  COVID-19 Autopsies, Oklahoma, USA.

Authors:  Lisa M Barton; Eric J Duval; Edana Stroberg; Subha Ghosh; Sanjay Mukhopadhyay
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

6.  New inflammatory indicators: association of high eosinophil-to-lymphocyte ratio and low lymphocyte-to-monocyte ratio with smoking.

Authors:  Yusuf Çekici; Mücahid Yılmaz; Özlem Seçen
Journal:  J Int Med Res       Date:  2019-07-18       Impact factor: 1.671

7.  Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.

Authors:  Jingyuan Liu; Yao Liu; Pan Xiang; Lin Pu; Haofeng Xiong; Chuansheng Li; Ming Zhang; Jianbo Tan; Yanli Xu; Rui Song; Meihua Song; Lin Wang; Wei Zhang; Bing Han; Li Yang; Xiaojing Wang; Guiqin Zhou; Ting Zhang; Ben Li; Yanbin Wang; Zhihai Chen; Xianbo Wang
Journal:  J Transl Med       Date:  2020-05-20       Impact factor: 5.531

Review 8.  Activation of toll-like receptor signaling pathways leading to nitric oxide-mediated antiviral responses.

Authors:  Mohamed Sarjoon Abdul-Cader; Aruna Amarasinghe; Mohamed Faizal Abdul-Careem
Journal:  Arch Virol       Date:  2016-05-27       Impact factor: 2.574

9.  Eosinopenia is associated with greater severity in patients with coronavirus disease 2019.

Authors:  Lei Zhao; Ye-Ping Zhang; Xinchun Yang; Xin Liu
Journal:  Allergy       Date:  2020-07-13       Impact factor: 14.710

10.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

View more
  4 in total

1.  Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance.

Authors:  Nikolaos Mathioudakis; Marinos Zachiotis; Stavros Papadakos; Maria Triantafyllou; Amalia Karapanou; Stamatia Samara; Georgios Karamanakos; Demetrios A Spandidos; Petros Papalexis; Christos Damaskos; Kyriakos Tarantinos; George Fotakopoulos; Pagona Sklapani; Nikolaos Trakas; Nikolaos V Sipsas; Vasiliki Epameinondas Georgakopoulou
Journal:  Exp Ther Med       Date:  2022-09-16       Impact factor: 2.751

Review 2.  Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.

Authors:  Eva Knuplez; Eva Maria Sturm; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

3.  Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes.

Authors:  Vasiliki E Georgakopoulou; Panagiotis Lembessis; Charalampos Skarlis; Aikaterini Gkoufa; Nikolaos V Sipsas; Clio P Mavragani
Journal:  Front Med (Lausanne)       Date:  2022-03-17

4.  Immature granulocytes: Innovative biomarker for SARS‑CoV‑2 infection.

Authors:  Vasiliki Epameinondas Georgakopoulou; Sotiria Makrodimitri; Maria Triantafyllou; Stamatia Samara; Pantazis M Voutsinas; Amalia Anastasopoulou; Chrysovalantis V Papageorgiou; Demetrios A Spandidos; Aikaterini Gkoufa; Petros Papalexis; Euthalia Xenou; Georgios Chelidonis; Pagona Sklapani; Nikolaos Trakas; Nikolaos V Sipsas
Journal:  Mol Med Rep       Date:  2022-05-13       Impact factor: 3.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.